IP Library Granted Patent US 9,540,326
Granted Patent B2
US 9,540,326 · App. 14/688,216 · Granted Jan 10, 2017

Prolyl hydroxylase inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,540,326
App. No.
14/688,216
Granted
Jan 10, 2017
Kind
B2
Abstract

Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1α), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.

Claims (22)

1. A compound of the formula:

wherein Z has the formula:

each R is independently a halogen;

n is an integer from 1 to 5; and

R 4 is alkyl; or

a pharmaceutically-acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, and citrate.

3. A method for treating an infection, the method comprising administering to a subject in need thereof a therapeutically-effective amount of a compound having the formula:

wherein Z has the formula:

each R is independently a halogen;

n is an integer from 1 to 5; and

R 4 is alkyl; or

a pharmaceutically-acceptable salt thereof.

4. The method of claim 3 , wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, and citrate.

5. The method of claim 3 , wherein the infection is caused by a virus.

6. The method of claim 3 , wherein the infection is caused by a bacterium.

7. The method of claim 6 , wherein the bacterium is Staphylococcus aureus.

8. The method of claim 3 , wherein the infection is caused by a fungus.

9. The method of claim 8 , wherein the fungus is a yeast.

10. The method of claim 6 , wherein the bacterium is methicillin resistant Staphylococcus aureus.

11. The method of claim 6 , wherein the bacterium is Streptococcus pyogenes.

12. The method of claim 6 , wherein the bacterium is Pseudomonas aeruginosa.

Assignments (6)
CHANGE OF NAME Recorded Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049919/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: WU, SHENGDE
To: THE PROCTOR & GAMBLE COMPANY
Reel/Frame 047110/0896 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: THE PROCTOR & GAMBLE COMPANY
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 047111/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: AKEBIA THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 047111/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS, INC
Reel/Frame 047642/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2015
From: GARDNER, JOSEPH H.; SHALWITZ, ROBERT
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 036868/0282 →